Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
J Zuber, F Fakhouri, LT Roumenina, C Loirat… - Nature Reviews …, 2012 - nature.com
In the past decade, a large body of evidence has accumulated in support of the critical role
of dysregulation of the alternative complement pathway in atypical haemolytic uraemic
syndrome (aHUS) and C3 glomerulopathies. These findings have paved the way for
innovative therapeutic strategies based on complement blockade, and eculizumab, a
monoclonal antibody targeting the human complement component 5, is now widely used to
treat aHUS. In this article, we review 28 case reports and preliminary data from 37 patients …
of dysregulation of the alternative complement pathway in atypical haemolytic uraemic
syndrome (aHUS) and C3 glomerulopathies. These findings have paved the way for
innovative therapeutic strategies based on complement blockade, and eculizumab, a
monoclonal antibody targeting the human complement component 5, is now widely used to
treat aHUS. In this article, we review 28 case reports and preliminary data from 37 patients …
[CITATION][C] Bacchi V; French Study Group for aHUS/C3 G. Use of eculizumab for atypical haemolytic uraemic 約 drome and C3 glomerulopathies.
J Zuber - Nat Rev Nephrol., 2012 - cir.nii.ac.jp
Bacchi V; French Study Group for aHUS/C3 G. Use of eculizumab for atypical haemolytic
uraemic 約drome and C3 glomerulopathies. | CiNii Research CiNii 国立情報学研究所 学術
情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本を
さがす 日本の博士論文をさがす English 検索 タイトル 人物/団体名 所属機関 ISSN DOI 期間 ~
本文リンク 本文リンクあり データソース JaLC IRDB Crossref DataCite NDL NDL-Digital RUDA
JDCat NINJAL CiNii Articles CiNii Books CiNii Dissertations DBpedia Nikkei BP KAKEN …
uraemic 約drome and C3 glomerulopathies. | CiNii Research CiNii 国立情報学研究所 学術
情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本を
さがす 日本の博士論文をさがす English 検索 タイトル 人物/団体名 所属機関 ISSN DOI 期間 ~
本文リンク 本文リンクあり データソース JaLC IRDB Crossref DataCite NDL NDL-Digital RUDA
JDCat NINJAL CiNii Articles CiNii Books CiNii Dissertations DBpedia Nikkei BP KAKEN …